{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:51:38Z","timestamp":1791337898133,"version":"4.3.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018674","name":"Barbara und Wilfried Mohr-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GM1909A"],"award-info":[{"award-number":["01GM1909A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GM1909E"],"award-info":[{"award-number":["01GM1909E"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.isci.2025.114564","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:24:51Z","timestamp":1766993091000},"page":"114564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1866-7116","authenticated-orcid":false,"given":"Anna S.","family":"Kolodziejczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Selt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Peterziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Jamaladdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Maa\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Meulenbroeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Sigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El Damaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Holland-Letz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Kutscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.P.","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian W.","family":"Pajtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Milde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114564_bib1","first-page":"1365","article-title":"Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome","volume":"43","author":"Li","year":"1969","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2025.114564_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10147-021-02011-w","article-title":"Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1","volume":"26","author":"Kumamoto","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib4","first-page":"608","article-title":"Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome","volume":"56","author":"Frebourg","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.isci.2025.114564_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/humu.10185","article-title":"Germline TP53 mutations and Li-Fraumeni syndrome","volume":"21","author":"Varley","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.isci.2025.114564_bib6","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","article-title":"Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis","volume":"7","author":"Kratz","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jmg.2009.073429","article-title":"TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes","volume":"47","author":"Ruijs","year":"2010","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.isci.2025.114564_bib9","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib10","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/neuonc\/noad114","article-title":"Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome","volume":"25","author":"Kolodziejczak","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib11","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.isci.2025.114564_bib13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/humu.23910","article-title":"A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically","volume":"41","author":"Coffee","year":"2020","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.isci.2025.114564_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-5-104","article-title":"Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome","volume":"5","author":"Heymann","year":"2010","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib16","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1002\/cam4.3427","article-title":"Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2025.114564_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-020-05612-7","article-title":"Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome","volume":"181","author":"Le","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.isci.2025.114564_bib18","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114564_bib19","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114564_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mrgentox.2015.05.010","article-title":"A new genotoxicity assay based on p53 target gene induction","volume":"789\u2013790","author":"Zerdoumi","year":"2015","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.isci.2025.114564_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2018.06.011","article-title":"Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations","volume":"101","author":"Kasper","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2025.114564_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/em.20634","article-title":"Comparison of in vitro micronucleus and gene mutation assay results for p53-competent versus p53-deficient human lymphoblastoid cells","volume":"52","author":"Honma","year":"2011","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.isci.2025.114564_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2021.11.030","article-title":"Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies","volume":"162","author":"Keller","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2025.114564_bib24","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/cncr.34786","article-title":"Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma","volume":"129","author":"Cole","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2025.114564_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114564_bib26","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1158\/1078-0432.CCR-17-0983","article-title":"Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-022-04436-0","article-title":"Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice","volume":"89","author":"Kiesel","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.isci.2025.114564_bib28","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","article-title":"WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe","volume":"17","author":"De Witt Hamer","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1476-4598-13-72","article-title":"Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma","volume":"13","author":"Harris","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2025.114564_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Ror\u00e0","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib31","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1038\/s41598-021-83809-6","article-title":"3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination","volume":"11","author":"Roper","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114564_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.398","article-title":"Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance","volume":"8","author":"Bingel","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2025.114564_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10048-006-0032-6","article-title":"Gene expression analyses reveal molecular relationships among 20 regions of the human CNS","volume":"7","author":"Roth","year":"2006","journal-title":"Neurogenetics"},{"key":"10.1016\/j.isci.2025.114564_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114564_bib35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral Heterogeneity within Medulloblastoma Subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.114564_bib36","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.cell.2020.10.044","article-title":"Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer","volume":"183","author":"Petralia","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114564_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143487","article-title":"Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer","volume":"13","author":"Lu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.114564_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12935-023-03057-8","article-title":"Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia","volume":"23","author":"Bell","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2025.114564_bib39","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/0008-5472.CAN-22-3702","article-title":"High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer","volume":"83","author":"Mayoh","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 Inhibitor: Clinical Development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.isci.2025.114564_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/cc.2.1.249","article-title":"Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol","volume":"2","author":"Pepper","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2025.114564_bib42","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1073\/pnas.92.19.8876","article-title":"Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance","volume":"92","author":"Ford","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114564_bib43","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/1535-7163.MCT-11-0469","article-title":"Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines","volume":"10","author":"Sarcar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114564_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-15-0692","article-title":"Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma","volume":"15","author":"Lescarbeau","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114564_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1541-7786.MCR-18-0860","article-title":"Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition","volume":"17","author":"Diab","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib46","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1158\/1078-0432.CCR-17-0947","article-title":"Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib47","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors","volume":"33","author":"Do","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib48","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib49","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(18)30204-3","article-title":"Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial","volume":"19","author":"Robinson","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib51","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/jamaoncol.2021.2224","article-title":"Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group","volume":"7","author":"Leary","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib52","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/1078-0432.CCR-23-2959","article-title":"Phase I\/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcS\u00e9-ESMART Trial","volume":"30","author":"Gatz","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib53","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-14-2588","article-title":"The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma","volume":"21","author":"Pokorny","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib54","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2020.38.15_suppl.2568","article-title":"Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study","volume":"38","author":"Romo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib55","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib57","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"Pitz","year":"2011","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib58","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3174\/ajnr.A3990","article-title":"MRI surrogates for molecular subgroups of medulloblastoma","volume":"35","author":"Perreault","year":"2014","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"10.1016\/j.isci.2025.114564_bib59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuchi.2017.10.003","article-title":"Imaging features of medulloblastoma: Conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: From general features to subtypes and characteristics","volume":"67","author":"Dangouloff-Ros","year":"2021","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.isci.2025.114564_bib60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.114564_bib61","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41419-023-06167-3","article-title":"Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth","volume":"14","author":"Della Monica","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2025.114564_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1535-7163.MCT-12-0735","article-title":"WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas","volume":"12","author":"Caretti","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114564_bib63","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/neuonc\/not220","article-title":"Targeting Wee1 for the treatment of pediatric high-grade gliomas","volume":"16","author":"Mueller","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-020-03457-0","article-title":"Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine","volume":"147","author":"Moreira","year":"2020","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-014-1514-2","article-title":"In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models","volume":"119","author":"Leten","year":"2014","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib66","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/neuonc\/noaa266","article-title":"Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier","volume":"23","author":"Genovesi","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1101522","article-title":"Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models","volume":"13","author":"Morris","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828684","article-title":"Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1","volume":"12","author":"Bukhari","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib69","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1538-7445.AM2023-6185","article-title":"Abstract 6185: Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma","volume":"83","author":"Piggott","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib70","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.1073\/pnas.1911229117","article-title":"Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma","volume":"117","author":"Kim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114564_bib71","article-title":"Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity","volume":"32","author":"Hwang","year":"2021","journal-title":"Nanomedicine."},{"key":"10.1016\/j.isci.2025.114564_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2020.11.028","article-title":"Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma","volume":"499","author":"Infante","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2025.114564_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061220","article-title":"Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo","volume":"13","author":"MacDonald","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.114564_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121138","article-title":"Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma","volume":"278","author":"Kumar","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.isci.2025.114564_bib75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib76","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","article-title":"Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)","volume":"26","author":"Cole","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib77","article-title":"Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study","volume":"4","author":"Mueller","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.isci.2025.114564_bib78","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/neuonc\/noab127","article-title":"Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model","volume":"23","author":"Simovic","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123400","article-title":"A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells 10","volume":"10","author":"Reed","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114564_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7401","article-title":"Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma","volume":"13","author":"Endersby","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.114564_bib81","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030064","article-title":"Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine","volume":"10","author":"Goto","year":"2020","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.isci.2025.114564_bib83","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2017.07.004","article-title":"Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53","volume":"38","author":"Zhou","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.isci.2025.114564_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.114564_bib85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau5147","article-title":"Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma","volume":"11","author":"Purzner","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2025.114564_bib87","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-018-0207-3","article-title":"A biobank of patient-derived pediatric brain tumor models","volume":"24","author":"Brabetz","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114564_bib88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1020630214549","article-title":"Chemosensitivity of glioblastoma cells during treatment with the organo-tin compound triethyltin(IV)lupinylsulfide hydrochloride","volume":"60","author":"Barbieri","year":"2002","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.isci.2025.114564_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0014-5793(95)00949-A","article-title":"Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro","volume":"372","author":"Moriyama","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.isci.2025.114564_bib90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/carcin\/7.6.879","article-title":"Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea","volume":"7","author":"Bodell","year":"1986","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.isci.2025.114564_bib91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.isci.2025.114564_bib92","first-page":"4229","article-title":"Normal cytotoxic response of skin fibroblasts from patients with Li-Fraumeni familial cancer syndrome to DNA-damaging agents in vitro","volume":"47","author":"Little","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114564_bib93","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/15384101.2016.1138188","article-title":"Cytokinetic effects of Wee1 disruption in pancreatic cancer","volume":"15","author":"Chang","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2025.114564_bib94","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41388-023-02681-y","article-title":"Atypical teratoid\/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities","volume":"42","author":"Paassen","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2025.114564_bib95","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114564_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041534","article-title":"Micronucleus Assay: The State of Art, and Future Directions","volume":"21","author":"Sommer","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114564_bib97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12079-021-00661-z","article-title":"Tools used to assay genomic instability in cancers and cancer meiomitosis","volume":"16","author":"Gantchev","year":"2022","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.isci.2025.114564_bib98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cels.2019.06.005","article-title":"A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines","volume":"9","author":"Niepel","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.isci.2025.114564_bib99","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.isci.2025.114564_bib100","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1038\/s41598-021-82017-6","article-title":"Methods and open-source toolkit for analyzing and visualizing challenge results","volume":"11","author":"Wiesenfarth","year":"2021","journal-title":"Sci. Rep."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225028251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225028251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:19:26Z","timestamp":1791335966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225028251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589004225028251"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114564","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114564"}}